Business Overview
Theravance Biopharma, Inc. operates with a primary focus on delivering medicines designed to make a meaningful difference in patients’ lives. The cornerstone of the company’s current commercial portfolio is the FDA-approved inhalation solution. YUPELRI holds the distinction of being the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) bronchodilator approved in the United States for the maintenance treatment of patients suffering from chronic obstructive pulmonary disease (COPD). In the U.S. market, commercialization of YUPELRI is spearheaded by Viatris, with Theravance Biopharma actively co-promoting the product under a structured profit and loss sharing arrangement. Under this agreement, Viatris retains 65% of the profit or loss, while Theravance Biopharma captures the remaining 35%. The company’s management has reiterated its overarching commitment to creating and driving shareholder value.
Key Financial Performance Highlights
Theravance Biopharma demonstrated a significant transition in its financial profile during the fourth quarter and full year of 2025, heavily bolstered by milestone payments.
- Total Revenue: For Q4 2025, total revenue was reported at $45.9 million, a substantial increase compared to $18.8 million in the same period of 2024. The Q4 2025 revenue consisted of $20.9 million in Viatris collaboration revenue and $25.0 million in licensing and milestone revenue triggered by YUPELRI’s performance. For the full year 2025, total revenue reached $107.5 million, up from $64.4 million in the full year 2024.
- Net Income / Loss: The company recorded a GAAP net income of $61.0 million for the fourth quarter of 2025, representing a stark turnaround from a net loss of $15.5 million in the fourth quarter of 2024. This positive net income was driven heavily by the realization of key sales milestones, specifically the $25.0 million from YUPELRI and $50.0 million from TRELEGY. For the full year 2025, GAAP net income was $105.9 million, compared to a net loss of $56.4 million in 2024.
- Non-GAAP Profitability: Theravance achieved an all-time high in non-GAAP profitability for the second consecutive quarter. Non-GAAP net income from operations was $3.1 million in Q4 2025, contrasting with a non-GAAP net loss of $2.5 million in Q4 2024. For the full year 2025, the non-GAAP net loss was $7.5 million, marking an improvement from a $16.2 million loss in 2024.
- Operating Expenses: Total costs and expenses for Q4 2025 were $25.9 million, a reduction from $28.0 million in Q4 2024. Research and Development (R&D) expenses in Q4 2025 were $7.4 million, down from $9.5 million in Q4 2024, primarily driven by the near completion of the CYPRESS clinical trial. Selling, General, and Administrative (SG&A) expenses remained flat year-over-year at $18.5 million for Q4 2025.
- Share-Based Compensation: Total share-based compensation expenses for Q4 2025 were $4.5 million, a reduction from $5.8 million in the corresponding period of 2024. Full-year 2025 share-based compensation was $18.5 million, successfully falling within the company’s financial guidance range of $18 million to $20 million.
- Income Taxes: Income tax expense for Q4 2025 rose to $12.0 million, compared to $6.6 million in Q4 2024. This increase was primarily attributed to taxes levied on the $50.0 million TRELEGY milestone income recognized during the quarter.
- Balance Sheet and Cash Position: The company ended 2025 with $326.5 million in cash, cash equivalents, and marketable securities. Factoring in the recent $25.0 million YUPELRI milestone and the $50.0 million TRELEGY milestone, the cash position is projected to reach approximately $400.0 million by the end of Q1 2026, operating with zero debt. Total assets as of December 31, 2025, were $485.6 million, an increase from $354.2 million at the end of 2024, while shareholders’ equity increased to $296.7 million from $175.5 million year-over-year.
Segment and Business-Line Performance
YUPELRI :
- The respiratory asset achieved record brand profitability for both the fourth quarter and the full year of 2025.
- Viatris reported total U.S. net sales for YUPELRI of $266.6 million for the full year 2025, marking a 12% year-over-year increase compared to full-year 2024. This performance successfully triggered a $25.0 million sales-based milestone payment from Viatris, which Theravance received in January 2026.
- For the fourth quarter of 2025 specifically, total U.S. net sales were $70.6 million, reflecting a 6% year-over-year increase from Q4 2024. This growth was underscored by robust underlying customer demand, which grew by 14% year-over-year, though partially offset by the timing of customer purchasing patterns.
- Doses pulled through the hospital channel increased by 13% year-over-year in Q4 2025, demonstrating solid, continued operational growth within that setting.
- Theravance Biopharma’s implied 35% share of the YUPELRI net sales for Q4 2025 amounted to $24.7 million, representing a 6% increase compared to the $23.3 million recorded in Q4 2024.
- Viatris collaboration revenue was $20.9 million for the fourth quarter, up 11% ($2.1 million) from the same period in 2024.
TRELEGY Economic Interest:
- GSK, the commercializing entity for TRELEGY, reported global net sales of approximately $970 million for the fourth quarter of 2025, representing a 14% increase versus the fourth quarter of 2024.
- For the full year 2025, GSK reported TRELEGY net sales of approximately $3.9 billion, representing a 13% year-over-year growth.
- Reaching this $3.9 billion full-year sales figure triggered a $50.0 million milestone payment from Royalty Pharma. This income was recognized in Q4 2025, and the cash was received by Theravance in February 2026.
- If global net sales of TRELEGY reach approximately $3.5 billion in full-year 2026, it will trigger an additional and final $100.0 million milestone payment from Royalty Pharma. Management expressed high confidence in achieving this upcoming 2026 milestone.
Management Commentary and Strategic Updates
A pivotal inflection point for Theravance Biopharma occurred in March 2026 regarding its clinical pipeline and corporate structure.
- CYPRESS Study and Wind-Down: The company announced that the Phase 3 CYPRESS study evaluating ampreloxetine failed to meet its primary endpoint. In response, management initiated a complete wind-down of the ampreloxetine program.
- Organizational Restructuring: Theravance launched an organizational restructuring plan designed to streamline costs and pivot resources entirely toward the commercial opportunity presented by YUPELRI. This entails a complete wind-down of the R&D organization, expected to be largely completed by early Q3 2026. Additionally, the General and Administrative (G&A) function will be reduced by approximately 50%. These actions are projected to impact roughly 50% of the company’s overall workforce.
- Financial Impact of Restructuring: The restructuring actions are anticipated to reduce operating expenses by approximately 60% compared to the 2025 actuals of $111.1 million. The full run-rate cost savings are projected to be around $70 million, materializing fully in the third quarter of 2026. The company expects to incur one-time cash severance costs of approximately $5 to $7 million over the next two quarters to execute these reductions.
- Cash Flow Projections: Through these significant cost savings combined with ongoing YUPELRI sales, Theravance projects it will generate between $60 million and $70 million in annualized cash flow starting in Q3 2026. This projection is based on an estimated $45 to $55 million of Income from Operations (excluding non-cash share-based compensation) alongside projected interest and other income, and completely excludes any potential capital from the upcoming $100 million TRELEGY milestone.
- Strategic Review Committee Actions: In 2024, the Board of Directors formed a Strategic Review Committee comprised entirely of independent directors to assess all strategic alternatives for the firm. Following the CYPRESS study results, this Committee, alongside independent financial advisor Lazard, accelerated its evaluation process. The Committee is currently acting with urgency to explore a broad spectrum of value-maximizing and tax-efficient alternatives, which explicitly includes the potential sale of the Company. Management noted there is no assurance that this process will result in any transaction and does not intend to provide further updates unless a disclosure is deemed appropriate or necessary.
- Executive Commentary: CEO Rick E. Winningham emphasized that Theravance concluded 2025 positively, pointing to the record non-GAAP profitability, the brand profitability for YUPELRI, and the capture of $75 million in key sales-based milestones. Winningham expressed confidence that the sweeping cost reductions combined with the ongoing work of the Strategic Review Committee will empower the company to maximize shareholder value moving forward.
- Investor Relations Update: The company announced it will no longer host earnings conference calls or webcasts; future quarterly results will be released exclusively via press release.
Notable Risks and Challenges
The Q4 2025 disclosures explicitly highlighted several forward-looking risks and operational challenges:
- Clinical Wind-Down Friction: The recent failure of the Phase 3 CYPRESS study presents transitional risks, including potential delays or unforeseen difficulties in winding down clinical studies for the ampreloxetine program.
- Expense and Profitability Volatility: Financial risks exist regarding factors that could increase the company’s expenses beyond current management expectations or otherwise adversely impact projected profitability targets.
- Milestone Uncertainty: While management expressed confidence, there remains structural uncertainty regarding whether the required threshold for the future $100 million TRELEGY milestone will ultimately be achieved.
- Strategic Transaction Ambiguity: The execution and timing of any potential strategic transaction evaluated by the Strategic Review Committee remain highly uncertain, with no absolute guarantee that a deal (such as a sale of the company) will materialize.
- Third-Party Reliance: Operational risks persist concerning the heavy reliance on third parties—namely Viatris and GSK—to successfully develop, manufacture, and commercialize key products generating the company’s core revenues.
- Macro and Market Dynamics: Broader risks include volatility in the trading price of the company’s shares, ongoing challenges in enforcing intellectual property rights, and shifting general economic and market conditions.